Methodist Breast Center

Early Detection

Breast Cancer is a frightening diagnosis, but it's not the end of the story. Tremendous resources have been devoted to the development of new treatments and new therapies. Surgery, hormone therapy, chemotherapy and radiation are all possible treatments — and with new advancements, they can be more effective and have fewer side effects.

Early detection is key. According to the National Cancer Institute, when Breast Cancer is found early and still localized, the relative survival rate (measured at five years) is 97 percent.

Learn more about early detection.

Breast Imaging Center Opens - Upper Kirby

Getting a mammogram just got a lot easier with The Methodist Hospital's new facility in the Upper Kirby district, offering a central location with Texas Medical Center technology.

The Methodist Breast Imaging Center is a state-of-the-art facility on U.S. 59 and Kirby, led by Dr. Luz A. Venta, who is also medical director of the Methodist Breast Center in the Texas Medical Center. The facility offers digital mammography, high resolution ultrasound, and the latest MRI equipment - all in a peaceful and soothing setting. Patients needing additional diagnostic testing can undergo biopsies in the same location and on the same day. Read more...

Visit the Methodist Breast Imaging Center website.

Clinical Trials

1. Protocol Title: A randomized phase II study to evaluate the combination of ixabepilone plus capecitabine or docetaxel plus capecitabine in the treatment of metastatic breast cancer (IRB #1107-0225)
   Principal Investigator: Edgardo Rivera, M.D.
   Phone Number: (713) 441-5785
   
   

   - This study includes patients > 18 years of age, with metastatic breast cancer (first and second line of treatment). Measurable disease with HER2-positive subjects will be allowed if they have progressed after receiving treatment with trastuzumab or lapatinib. Subjects may be enrolled with triple-negative (TN) disease (not expressing ER, PR, or HER2/neu) or non-triple-negative (NTN) disease.

2. Protocol Title: Exploratory analysis of protein expression profiles in nipple aspiration fluid of breast cancer patients (IRB# 1107-0227)
   Principal Investigator: Edgardo Rivera, M.D.
   Phone Number: (713) 441-5785
   
   

   - Patients who are candidate for neoadjuvant chemotherapy, disease stage (T1N1-3M0 to T2-4 N0-3M0). Read more...